cabozantinib
ipsen
['gu ', 'solid tumor', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabopoint', 'ipsen']
cabopoint trial: interim analyses demonstrated preliminarv efficacy (orr) with cabozantinib in patients with arcc after cpi-based combination therapy, irrespective of 1l regimen (dcr: 83%, with 30.5% pr and 1.2% cr). #gu23 
Jefe de Servicio de Oncología Médica. Hospital Universitario Lucus Augusti, HULA. Grupo de Investigación Oncológica Traslacional, GIOT HULA. Cuenta personal